Short-course total neoadjuvant therapy improved five-year survival in STELLAR
Five-year overall survival was 78.1% with short-course total neoadjuvant therapy versus 69.7% with long-course chemoradiotherapy.
Latest research
Search the archiveFLASH proton therapy for lung cancer remains preclinical despite technical progress
Preclinical lung studies support normal-tissue sparing, but uncertain biological thresholds, dose conformity, and respiratory motion still prevent clinical implementation.
Automated lattice radiotherapy evaluation cut analysis time nearly eightfold
An Eclipse-based tool reduced lattice plan evaluation from 15.4 to 2.0 minutes while maintaining close agreement with manual measurements.
Stereotactic radiotherapy plus atezolizumab missed the AZTEC efficacy target
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Complete resection dominated survival outcomes in post-radiation sarcoma
Positive margins more than doubled mortality risk and quadrupled local recurrence risk in a meta-analysis of 2,438 post-radiation sarcoma patients.
Preoperative stereotactic radiotherapy shortened brain metastasis treatment without increasing early morbidity
Preoperative SRS/FSRT completed local therapy 22.5 days sooner than postoperative treatment, with similar 30-day morbidity; oncologic outcomes remain pending.
Respiratory gating reduced lung SBRT target volumes and normal-tissue dose
A 30–70% gating window reduced planning target volume by 34% and mean lung dose by 0.75 Gy without compromising coverage.
USP15-FIS1 signaling sensitized bladder cancer to radiotherapy through mitochondrial dysfunction
USP15 stabilized FIS1, suppressed oxidative phosphorylation, and increased radiosensitivity; metformin restored radiation response in USP15-low bladder cancer models.
Pan-cancer gene expression predicted progression after radiotherapy across five cancer types
Leave-one-cancer-type-out genomic scores remained associated with progression in five of eight cancers, with the largest performance gain in cervical cancer.
AI-assisted VMAT planning shortened workflow but required manual hotspot correction
AI-assisted planning cut average planning time from about two hours to 30 minutes, but three of 12 plans required manual hotspot correction.
Geometry-based scaling standardized central target definition for SCART planning
A phantom-derived model predicted SCART central target radius with R² values of 0.991–0.999, but clinical validation remains absent.
SGRT reduced pelvic pitch and longitudinal setup errors in vulvar radiotherapy
In 20 vulvar cancer patients, SGRT reduced pitch error from 1.21° to 0.07° and longitudinal error from 4.9 to 0.4 mm.
Helium pencil beam commissioning achieved submillimetre range accuracy and robust dose agreement
A scanned helium beamline achieved submillimetre range accuracy and generally ≤3% dose agreement, supporting further translation toward clinical helium therapy.
Cardiac-dose model validated non-cancer death risk in one lung SBRT cohort
The model calibrated well only when non-cancer death was defined consistently; an overall-survival version validated in both external cohorts.
Patient-specific 3D-printed templates enabled efficient brachytherapy for complex cervical cancer
Template-guided implantation achieved a median HR-CTV D90 of 92.9 Gy with low severe toxicity across 555 brachytherapy fractions.